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In this issue of Cell, Park et al. (2007) describe the nuclear encoded protein MTERF3 as a nega-
tive regulator of mitochondrial DNA transcription initiation. This study highlights a mechanism 
by which mitochondrial DNA transcription (and therefore oxidative phosphorylation) may be 
regulated in response to alterations in the cell’s physiological and metabolic demands.Mitochondria are ubiquitous 
organelles found in all nucle-
ated cells and are the primary 
generators of cellular ATP 
by oxidative phosphorylation 
(OXPHOS). OXPHOS depends 
upon the coordinated expres-
sion, interaction, and regula-
tion of both nuclear genes and 
the mitochondrial genome 
(mtDNA). The latter is a 16.6 
kb circular DNA molecule that 
encodes 13 essential polypep-
tides of the OXPHOS system 
and the necessary RNA machin-
ery (2 rRNAs and 22 tRNAs) 
for the translation of mtDNA 
transcripts. mtDNA has two 
strands, a guanine-rich heavy 
strand and a cytosine-rich light 
strand. Transcription from the 
heavy strand generates all 13 
mRNAs with the exception of 
ND6 (Figure 1). The mitochon-
drial genome is remarkably 
compact in terms of the orga-
nization of its genetic material, 
with the only major region of 
noncoding sequence, the 1.1 
kb control region, containing 
important regulatory elements 
for mtDNA expression (Asin-
Cayuela and Gustafsson, 2007). 
In this issue, Park et al. (2007) 
identify a nuclear encoded pro-
tein, MTERF3, as the first nega-
tive regulator of mitochondrial 
DNA transcription.Figure 1. MTERF3 Is a Regulator of Mitochondrial 
DNA Transcription
Shown is a map of the 16.6 kb circular, double-stranded mi-
tochondrial genome encoding 13 proteins, 22 tRNAs, and 2 
rRNAs. The 1.1 kb noncoding control region is shown in linear 
form. Transcription of the heavy strand is initiated either from 
the heavy-strand promoter 1 (HSP1), generating a short tran-
script that terminates at the 16S rRNA, or from HSP2, gener-
ating a polycistronic message including both rRNA genes, 12 
mRNA genes, and 14 tRNA genes. Light-strand transcription 
from the light-strand promoter (LSP) generates the ND6 mRNA 
and 8 tRNAs. Transcription from all promoters requires the in-
volvement of the transcriptional activator TFAM that binds up-
stream of the promoters, together with a single subunit RNA 
polymerase (POLRMT), which forms a heterodimeric complex 
with one of two transcription factors, TFB1M or TFB2M. To-
gether with as yet unidentified interacting partners that are 
crucial for its function, MTERF3 acts as a negative regulator 
of transcription by binding to mitochondrial DNA at or near the 
light-strand promoter and heavy-strand promoters.Cell 130, JulyMuch of our understand-
ing of the basic principles of 
mitochondrial genetics, inher-
itance, and gene expression 
has arisen from the study of 
disease pathology. Patients 
with mitochondrial diseases, 
specifically respiratory chain 
disorders, harbor either spo-
radic or maternally transmit-
ted mtDNA mutations, or 
mutations in nuclear genes 
involved in either mtDNA 
maintenance—such as the 
mtDNA polymerase γ (POLG1) 
gene—or respiratory chain 
complex assembly. These 
give rise to a spectrum of mul-
tisystem disorders that affect 
both children and adults. They 
commonly involve muscle and 
the central nervous system 
but can present with varying 
degrees of organ severity and 
specificity (Taylor and Turn-
bull, 2005). Moreover, mtDNA 
mutations have been impli-
cated in the aging process 
(Kirkwood, 2005); high levels 
of somatic mtDNA mutations 
have been identified in cells 
with an OXPHOS deficiency in 
both aging and neurodegen-
erative disorders (Bender et 
al., 2006), although their pre-
cise role continues to provoke 
much debate (Khrapko and 
Vijg, 2007). 27, 2007 ©2007 Elsevier Inc. 211
The principal mitochondrial tran-
scription machinery has been elu-
cidated and comprises a mitochon-
drial RNA polymerase (POLRMT), a 
mitochondrial transcription factor A 
(TFAM), and one of two homologous 
mitochondrial transcription factors, 
B1 (TFB1M) or B2 (TFB2M) (Falken-
berg et al., 2002). In spite of consid-
erable knowledge concerning the 
machinery involved, the regulation of 
mitochondrial transcription, its cou-
pling to protein translation, and ribo-
some biogenesis are poorly defined, 
although new regulatory proteins 
continue to be identified (Wang et al., 
2007). An understanding of these pro-
cesses is crucial not only for estab-
lishing the regulatory mechanisms 
and how these mechanisms fine tune 
mitochondrial function but also for 
elucidating the basis of mitochondrial 
disease. Given the recent finding of 
mutations in nuclear genes encoding 
ribosomal proteins and elongation 
factors leading to generalized defects 
in translation (Coenen et al., 2004), it 
is not unreasonable to speculate that 
human mitochondrial transcription 
defects may also represent an as 
yet undefined but important class of 
OXPHOS disorders.
The mitochondrial transcription ter-
mination factors are a group of DNA-
binding proteins including MTERF 
(also called MTERF1) that are thought 
to be involved in the regulation of mito-
chondrial transcription, although their 
functions and mechanism of action 
remain to be defined. Evidence for a 
new player in this process is provided 
in this issue of Cell by Larsson, Gus-
tafsson, and their colleagues (Park et 
al., 2007), who identify MTERF3, a pre-
viously uncharacterized mitochondrial 
protein, as a transcriptional repres-
sor through its binding to the mtDNA 
promoter region (Figure 1). Originally 
identified by PSI-BLAST searches of 
the NCBI protein sequence database, 
MTERF3 is ubiquitously expressed 
and shown by the authors to be tar-
geted to mitochondria. Confirmation 
of MTERF3’s role in cell viability and 
maintaining OXPHOS capacity is pro-
vided by elegant studies in mice lack-
ing MTERF3. Homozygous Mterf3 
knockout mouse embryos die at 212 Cell 130, July 27, 2007 ©2007 Elsevaround embryonic day (E)8.5; embry-
onic lethality was rescued by the 
reintroduction of the Mterf3 gene. 
Tissue-specific knockout of MTERF3 
in the heart revealed several features 
consistent with marked mitochon-
drial respiratory chain dysfunction. 
These mice had a shortened life span 
and enlarged hearts with increased 
numbers of abnormal mitochondria 
as detected by electron microscopy. 
These defects were associated with 
a progressive loss of MTERF3 protein 
and a marked reduction in the levels 
of assembled respiratory chain com-
plexes containing mtDNA-encoded 
subunits. Direct enzyme measure-
ments confirmed multiple respira-
tory chain deficiencies and increased 
citrate synthase activity in agreement 
with the electron microscopy findings.
Hearts lacking MTERF3 had normal 
mtDNA levels and, surprisingly, exhib-
ited increased steady-state levels of 
RNA19 (a well-defined transcript pre-
cursor encompassing 16S rRNA and 
ND1, which is known to accumulate 
in patients with mt-tRNALeu(UUR) muta-
tions) and of some tRNAs (transcribed 
from either the light-strand promoter 
or the heavy-strand promoter). Inter-
estingly, steady-state levels of tRNAs 
close to the light-strand promoter 
or the heavy-strand promoter were 
increased, whereas tRNAs distal to 
the promoters showed decreased 
steady-state levels. In addition, chro-
matin immunoprecipitation analyses 
with MTERF3 antibodies showed 
binding to mtDNA at or near the light-
strand promoter or the heavy-strand 
promoter, implying that MTERF3 
might affect transcription initiation. 
Direct assays subsequently revealed 
that mtDNA transcription initiation 
indeed was increased from both 
promoters in mitochondria lack-
ing MTERF3. Finally, to verify a role 
for MTERF3 in transcription repres-
sion, the authors measured de novo 
mtDNA transcription in mitochondrial 
extracts before and after MTERF3 
immunodepletion. Addition of exog-
enous MTERF3 could not rescue 
transcriptional activity, suggesting 
that MTERF3 depletion leads to loss 
of other interacting factors required 
for its function.ier Inc.These observations raise some 
fascinating insights into the role of 
MTERF3, not the least of which is 
the potential mechanism by which 
the MTERF3 knockout mice develop 
respiratory chain dysfunction in heart 
tissue. It is surprising that heart muscle 
cells that lack MTERF3 have enhanced 
mitochondrial transcription yet exhibit 
such a severe biochemical defect. The 
authors present data suggesting that 
decreased levels of certain tRNAs 
cause the respiratory chain deficiency. 
However, we propose an alternate pos-
sibility, namely that it is the proportion 
of transcripts and not their abundance 
per se that plays a role in regulating 
mitochondrial translational activity. 
In this regard, an additional but as 
yet undetermined role for MTERF3 
may be important. Both TFB1M and 
TFB2M transcription factors have 
strong sequence homology with bac-
terial rRNA methyltransferases, which 
has led some to speculate that these 
proteins may possess a bifunctional 
role, namely the recognition of specific 
DNA sequences to facilitate promoter 
recognition by the single subunit RNA 
polymerase POLRMT (Falkenberg et 
al., 2002). Increased levels of RNA19 
in MTERF3-deficient organelles sug-
gest that MTERF3 may be important 
in RNA processing; and data from 
Drosophila indicate its possible role in 
controlling mitochondrial translation in 
flies (Roberti et al., 2006).
The identification of MTERF3 repre-
sents a major step in defining the pre-
cise molecular machinery in mammals 
that controls mitochondrial transcrip-
tion in vivo, with studies in mice high-
lighting a new disease mechanism that 
leads to mitochondrial respiratory chain 
deficiency. Ongoing studies will be of 
great importance in providing not only 
a greater understanding of basic mito-
chondrial physiology but also insights 
into possible therapeutic interventions 
for treating disorders associated with 
mitochondrial DNA-mediated respira-
tory chain dysfunction.
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